December 16: The Week in Cancer News
A second KRAS inhibitor is approved for lung cancer, and a BTK inhibitor challenges standard of care for relapsed or refractory CLL.
Progress Against Cancer
A second KRAS inhibitor is approved for lung cancer, and a BTK inhibitor challenges standard of care for relapsed or refractory CLL.
The new AKT inhibitor doubled progression-free survival when added to treatment with Faslodex.
Study finds pausing endocrine therapy is safe for early-stage breast cancer patients eager to expand their families.
A second inhibitor of the difficult-to-target KRAS protein was approved to treat certain lung cancers. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to adagrasib (Krazati) for adult patients with locally...
Black breast cancer patients had worse outcomes in a recent study, even when cancer features aligned with white patients.
Medical marijuana used as a substitute for opioids, and chemo and endocrine therapy together increase cancer-related cognitive impairment.
The FDA approved the PD-L1 inhibitor atezolizumab to treat alveolar soft part sarcoma The U.S. Food and Drug Administration has approved atezolizumab (Tecentriq) for the treatment of patients 2 years of age or older...
AACR patient advocate forum explores how new clinical trial designs are accelerating drug testing.
Oncologists report that prior authorization interrupts cancer care, plant-based diet is associated with lower colorectal cancer risk in men, and more from this week in cancer news.
A second inhibitor of mutant IDH1 was approved to treat certain blood cancers. The U.S. Food and Drug Administration (FDA) has approved olutasidenib (Rezlidhia) for patients with relapsed or refractory acute myeloid leukemia (AML)...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More